1736 related articles for article (PubMed ID: 16256090)
21. Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine.
Wang R; Yan H; Tang XC
Acta Pharmacol Sin; 2006 Jan; 27(1):1-26. PubMed ID: 16364207
[TBL] [Abstract][Full Text] [Related]
22. Regulating and assessing risks of cholinesterase-inhibiting pesticides: divergent approaches and interpretations.
Carlock LL; Chen WL; Gordon EB; Killeen JC; Manley A; Meyer LS; Mullin LS; Pendino KJ; Percy A; Sargent DE; Seaman LR; Svanborg NK; Stanton RH; Tellone CI; Van Goethem DL
J Toxicol Environ Health B Crit Rev; 1999; 2(2):105-60. PubMed ID: 10230391
[TBL] [Abstract][Full Text] [Related]
23. Reversal of cholinesterase inhibition and clinical signs and the postmortem findings in mice after intraperitoneal administration of anatoxin-a(s), paraoxon or pyridostigmine.
Cook WO; Dahlem AM; Harlin KS; Beasley VR; Hooser SB; Haschek WM; Carmicheal WW
Vet Hum Toxicol; 1991 Feb; 33(1):1-4. PubMed ID: 2017858
[TBL] [Abstract][Full Text] [Related]
24. [The monitoring of cholinesterases in farm workers and tradesmen exposed to phosphoric esters and carbamates].
Faustini A; Arpaia F; Pagliarella P; Forastiere F; Papini P; Perucci CA
Med Lav; 1992; 83(2):135-45. PubMed ID: 1630402
[TBL] [Abstract][Full Text] [Related]
25. Effect of coumaphos on cholinesterase activity, hematology, and biochemical blood parameters of bovines in tropical regions of Mexico.
Pardío VT; Ibarra Nde J; Waliszewski KN; López KM
J Environ Sci Health B; 2007 May; 42(4):359-66. PubMed ID: 17474014
[TBL] [Abstract][Full Text] [Related]
26. Long-term effects of human butyrylcholinesterase pretreatment followed by acute soman challenge in cynomolgus monkeys.
Sun W; Doctor BP; Lenz DE; Saxena A
Chem Biol Interact; 2008 Sep; 175(1-3):428-30. PubMed ID: 18674756
[TBL] [Abstract][Full Text] [Related]
27. Kinetic analysis of the protection afforded by reversible inhibitors against irreversible inhibition of acetylcholinesterase by highly toxic organophosphorus compounds.
Eckert S; Eyer P; Mückter H; Worek F
Biochem Pharmacol; 2006 Jul; 72(3):344-57. PubMed ID: 16780806
[TBL] [Abstract][Full Text] [Related]
28. The use of cholinesterases in ecotoxicology.
Nunes B
Rev Environ Contam Toxicol; 2011; 212():29-59. PubMed ID: 21432054
[TBL] [Abstract][Full Text] [Related]
29. Synthesis, in vitro pharmacology, and molecular modeling of very potent tacrine-huperzine A hybrids as acetylcholinesterase inhibitors of potential interest for the treatment of Alzheimer's disease.
Camps P; El Achab R; Görbig DM; Morral J; Muñoz-Torrero D; Badia A; Eladi Baños J; Vivas NM; Barril X; Orozco M; Luque FJ
J Med Chem; 1999 Aug; 42(17):3227-42. PubMed ID: 10464010
[TBL] [Abstract][Full Text] [Related]
30. Low-dose cholinesterase inhibitors do not induce delayed effects on cerebral blood flow and metabolism.
Scremin OU; Shih TM; Huynh L; Roch M; Sun W; Chialvo DR; Jenden DJ
Pharmacol Biochem Behav; 2005 Apr; 80(4):529-40. PubMed ID: 15820522
[TBL] [Abstract][Full Text] [Related]
31. Time course of cholinesterase inhibition in adult rats treated acutely with carbaryl, carbofuran, formetanate, methomyl, methiocarb, oxamyl or propoxur.
Padilla S; Marshall RS; Hunter DL; Lowit A
Toxicol Appl Pharmacol; 2007 Mar; 219(2-3):202-9. PubMed ID: 17197007
[TBL] [Abstract][Full Text] [Related]
32. Systemic administration of the potential countermeasure huperzine reversibly inhibits central and peripheral acetylcholinesterase activity without adverse cognitive-behavioral effects.
Myers TM; Sun W; Saxena A; Doctor BP; Bonvillain AJ; Clark MG
Pharmacol Biochem Behav; 2010 Jan; 94(3):477-81. PubMed ID: 19909771
[TBL] [Abstract][Full Text] [Related]
33. Differential sensitivity of blood, peripheral, and central cholinesterases in beagle dogs following dietary exposure to chlorpyrifos.
Marable BR; Maurissen JP; Mattsson JL; Billington R
Regul Toxicol Pharmacol; 2007 Apr; 47(3):240-8. PubMed ID: 17141929
[TBL] [Abstract][Full Text] [Related]
34. Weak inhibitors protect cholinesterases from strong inhibitors (paraoxon): in vitro effect of ranitidine.
Petroianu GA; Arafat K; Schmitt A; Hasan MY
J Appl Toxicol; 2005; 25(1):60-7. PubMed ID: 15669026
[TBL] [Abstract][Full Text] [Related]
35. Biochemical effects of low level exposure to soman vapour.
Bajgar J; Sevelová L; Krejcová G; Fusek J; Vachek J; Kassa J; Herink J; de Jong LP; Benschop H
Cent Eur J Public Health; 2004 Mar; 12 Suppl():S4-7. PubMed ID: 15141961
[TBL] [Abstract][Full Text] [Related]
36. Effects of acetylcholinesterase and butyrylcholinesterase inhibition on breathing in mice adapted or not to reduced acetylcholinesterase.
Boudinot E; Taysse L; Daulon S; Chatonnet A; Champagnat J; Foutz AS
Pharmacol Biochem Behav; 2005 Jan; 80(1):53-61. PubMed ID: 15652380
[TBL] [Abstract][Full Text] [Related]
37. Cholinesterase inhibition in chlorpyrifos workers: Characterization of biomarkers of exposure and response in relation to urinary TCPy.
Garabrant DH; Aylward LL; Berent S; Chen Q; Timchalk C; Burns CJ; Hays SM; Albers JW
J Expo Sci Environ Epidemiol; 2009 Nov; 19(7):634-42. PubMed ID: 18716607
[TBL] [Abstract][Full Text] [Related]
38. In vitro kinetic interactions of pyridostigmine, physostigmine and soman with erythrocyte and muscle acetylcholinesterase from different species.
Herkert NM; Thiermann H; Worek F
Toxicol Lett; 2011 Sep; 206(1):41-6. PubMed ID: 21414391
[TBL] [Abstract][Full Text] [Related]
39. Aging-resistant organophosphate bioscavenger based on polyethylene glycol-conjugated F338A human acetylcholinesterase.
Mazor O; Cohen O; Kronman C; Raveh L; Stein D; Ordentlich A; Shafferman A
Mol Pharmacol; 2008 Sep; 74(3):755-63. PubMed ID: 18523134
[TBL] [Abstract][Full Text] [Related]
40. An in vitro investigation of the effects of the nerve agent pretreatment pyridostigmine bromide on human peripheral blood T-cell function.
Telford G; Wilkinson LJ; Hooi DS; Worrall V; Green AC; Cook DL; Pritchard DI; Griffiths GD
Int Immunopharmacol; 2004 Nov; 4(12):1455-66. PubMed ID: 15351315
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
